Company overview
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing MBRX with another company.
| Daily close (USD) | $0.42 |
| Market capitalization (USD) | $3,010,400 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.26 |
No matching rows. Clear the filter to see all records.
Read MBRX's valuation metrics
Company size
Moleculin Biotech, Inc.'s recorded market capitalization is $3,010,400. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
MBRX's recorded price-to-book ratio is 0.26. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Moleculin Biotech, Inc. with Aurora
Use the snapshot above to ask a specific question about MBRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MBRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.